Main Article Content

Chanthaporn Imbumroong




Download data is not yet available.

Article Details

ยาน่ารู้ (Interesting Drugs)


1. Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354(9180):716-22.
2. Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, et al. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of a single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. Am Heart J 2003;146:27-32.
3. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358(9282):605-13.
4. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction. Circulation 2003;108:135-42.
5. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367(9510):569-78.
6. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013;368:1379-87.
7. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-77.
8. Vanscoy GJ, Rihn TL, Koerner PH. Tenecteplase: innovative fibrinolysis for ST-segment elevation myocardial infarction (STEMI). P&T® [Internet]. 2003 [cited 2019 Mar 19]; 28 (1): 20-30. Available from:
9. Metalyse 8,000 units. [Internet]. 2006 Feb 23 [ update 2017 Oct 25; cited 2019 Mar 19]. Available from: https://www.medicines.org.uk/emc/product/3012/smpc
10. Metalyse [Internet]. 2019 [cited 2019 Mar 19]. Available from: https://www.metalyse.com/metalyse
11. Michael M. Tenecteplase (TNKase™): A Clinical Review. Pharmacotherapy Update [Internet]. 2001 [cited 2019 Mar 19]; 4(1): Available from: https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/JanFeb2001/Tenecteplase.htm
12. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013
ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation [Internet]. 2013 [cited 2019 Mar19];127(4): e362-425. Available from: https://www.ahajournals.org/doi/pdf/10.1161/CIR.0b013e3182742cf6
13. Tenecteplase [Internet] 2005 June 13 [ update 2019 Feb 12; cited 2019 Mar 19]. Available from: https://www.drugbank.ca/drugs/DB00031
14. Tenecteplase [Internet] 2000 [update 2019 Feb 4; cited 2019 Mar19]. Available from:
15. Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003;89:1358–62.
16. Sitthisuk S.. Guideline for ischemic heart disease 2014. 2nd ed. Bangkok: 2019 The Heart Association of Thailand Under The Royal Patronage of H.M. The King; 2014. 72 p.